Role of lipid-lowering agents in the management of diabetic retinopathy

Table 1 Studies evaluating the effects of statins and fibrates on diabetic retinopathy

Ref.	Type of diabetes mellitus	n	Treatment	Dose (mg/d)	Follow-up (mo)	Outcome
[45]	1 and 2	50	Simvastatin	20	6	Delayed progression of retinopathy
[46]	2	18	Atorvastatin	20	12	Reduction of hard exudates and fluorescein leakage
[47]	2	30	Atorvastatin	10	4.5	Reduction of hard exudates but no effect on macular edema or visual acuity
[48]	2	30	Atorvastatin	20	6	No effect on hard exudates, macular edema or visual acuity
[49]	2	2838	Atorvastatin	10	47	No effect on the incidence of laser treatment or progression of retinopathy
[50]	2	5963	Simvastatin	40	58	No effect on the incidence of laser treatment
[59]	2	9795	Fenofibrate	200	60	Reduction of the need for laser photocoagulation and the risk of progression of retinopathy but no effect on the development of retinopathy in patients without retinopathy at baseline or on the risk of deterioration of visual acuity
[60]	2	2856	Fenofibrate	160	48	Reduction of the rate of progression of retinopathy but no effect on the occurrence of moderate vision loss